scPharmaceuticals reports preliminary Q4 FUROSCIX revenue $12M-$12.3M

“We continue to see FUROSCIX net revenue growth driven by our ongoing expansion efforts, including collaborations w ith top Integrated Delivery Networks and hospital systems, and the initial impact of our expanded field sales force,” stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals (SCPH). “As we enter 2025, we look forward to the first full quarter with our expanded sales force and anticipated further growth in Class IV heart failure patients. We anticipate additional growth with the implementation of the Medicare redesign and our upcoming PDUFA date in March to expand the FUROSCIX indication to include chronic kidney disease patients. We expect a mid-year submission of the sNDA for our Autoinjector product candidate which should accelerate future growth.”